Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | GGT1 | P19440 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | GNPAT | O15228 | 1/20 | 0.33 |
| ▸ | OTC | P00480 | 1/20 | 0.33 |
| ▸ | NPY4R | P50391 | 4/20 | 0.32 |
| ▸ | NPY1R | P25929 | 3/20 | 0.32 |
| ▸ | NPY2R | P49146 | 3/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.32 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL933117 | 1.00 | C3AR1 (0.38) | C3AR1FOLH1ALOX15GGT1MEN1 | |
| SCHEMBL29056187 | 0.90 | C3AR1 (0.38) | C3AR1FOLH1ALOX15GGT1MEN1 | |
| SCHEMBL5605498 | 0.89 | FOLH1 (0.38) | C3AR1FOLH1ALOX15GGT1MEN1 | |
| SCHEMBL1651878 | 0.87 | GNPAT (0.44) | GNPATNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL144726 | 0.87 | GGT1 (0.40) | C3AR1FOLH1ALOX15GGT1MEN1 | |
| SCHEMBL638493 | 0.86 | FOLH1 (0.41) | C3AR1FOLH1ALOX15GGT1GNPAT | |
| SCHEMBL7451685 | 0.86 | FOLH1 (0.41) | C3AR1FOLH1ALOX15GGT1GNPAT | |
| SCHEMBL28080169 | 0.85 | C3AR1 (0.39) | C3AR1FOLH1ALOX15GGT1MEN1 | |
| SCHEMBL1149706 | 0.85 | NOD1 (0.43) | C3AR1FOLH1ALOX15GGT1MEN1 | |
| SCHEMBL2438028 | 0.85 | C3AR1 (0.39) | C3AR1FOLH1ALOX15GGT1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022139613-A1 | BLOOD AND URINE-BASED TEST FOR PREDICTION OF PROGRESSION OF DIABETIC KIDNEY DISEASE | QATAR FOUNDATION FOR EDUCATION, SCIENCE AND COMMUNITY DEVELOPMENT (QA) | 2022-06-30 | — | — | WO | claimed |
| CN-114624362-A | Kit for detecting advanced glycosylation end products in serum and application thereof | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 2022-06-14 | — | — | CN | claimed |
| EP-3749960-A1 | METHODS FOR DIAGNOSING AN AUTISTIC SPECTRUM DISORDER | Qatar University (QA) | 2020-12-16 | — | — | EP | claimed |
| WO-2019155233-A1 | METHODS FOR DIAGNOSING AN AUTISTIC SPECTRUM DISORDER | RABBANI NAILA | 2019-08-15 | — | — | WO | claimed |
| US-20130040314-A1 | IMMUNOASSAY OF CARBOXYMETHYLARGININE | ARKRAY, INC. (JP) | 2013-02-14 | — | — | US | claimed |
| EP-2557423-A1 | Immunoassay of carboxymethylarginine | ARKRAY, Inc. (JP) | 2013-02-13 | — | — | EP | claimed |
| US-20120195989-A1 | Carboxymethylarginine Production Inhibitor and Collagen Denaturation Inhibitor | ARKRAY, INC. (JP) | 2012-08-02 | — | — | US | claimed |
| EP-2452690-A1 | CARBOXYMETHYLARGININE PRODUCTION INHIBITOR AND COLLAGEN DENATURATION INHIBITOR | Arkray, Inc. (JP) | 2012-05-16 | — | — | EP | claimed |
| US-20260137687-A1 | GTPase INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-21 | — | — | US | disclosed |
| EP-3248606-B1 | OXIDIZED PROTEIN HYDROLASE ACTIVITY ENHANCING AGENT AND GLYCATION STRESS INHIBITOR | ARKRAY INC (JP) | 2025-11-19 | — | — | EP | disclosed |
| EP-3248607-B1 | MAILLARD REACTION PRODUCT-DECOMPOSING AGENT | ARKRAY INC (JP) | 2025-11-19 | — | — | EP | disclosed |
| US-20250255795-A1 | CYCLIC PEROXIDE, OXIDATION REACTION PRODUCT, METHOD FOR PRODUCING OXIDATION REACTION PRODUCT, AND APPLICATIONS OF THESE | MEDIPLUS PHARMA, INC. (JP) | 2025-08-14 | — | — | US | disclosed |
| EP-4577200-A2 | GTPASE INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-02 | — | — | EP | disclosed |
| CN-119894505-A | GTPase inhibitors and uses thereof | 加利福尼亚大学董事会 | 2025-04-25 | — | — | CN | disclosed |
| US-6589944-B1 | A method of cleaving glycation endproducts or cross-linked proteins in an organism in need thereof, wherein said method comprises administering an effective amount of a compound or pharmaceutically acceptable salt thereof to said organism for | CITY OF HOPE | 2003-07-08 | — | — | US | disclosed |
| EP-1272172-A2 | USE OF BREAKERS OF ADVANCED GLYCATION ENDPRODUCTS FOR TREATING DELETERIOUS EFFECTS OF AGING AND DEBILITATING DISEASES | City of Hope (US) | 2003-01-08 | — | — | EP | disclosed |
| WO-2002076443-A1 | USE OF BREAKERS OF ADVANCED GLYCATION ENDPRODUCTS FOR TREATING DELETERIOUS EFFECTS OF AGING AND DEBILITATING DISEASES | CITY OF HOPE (US) | 2002-10-03 | — | — | WO | disclosed |
| WO-2002072083-A1 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGES) | CITY OF HOPE (US) | 2002-09-19 | — | — | WO | disclosed |
| US-20020002203-A1 | Novel breakers of advanced glycation endproducts | CITY OF HOPE | 2002-01-03 | — | — | US | disclosed |
| WO-2001076584-A2 | USE OF BREAKERS OF ADVANCED GLYCATION ENDPRODUCTS FOR TREATING DELETERIOUS EFFECTS OF AGING AND DEBILITATING DISEASES | CITY OF HOPE (US) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002203-A1 | Novel breakers of advanced glycation endproducts | AGER, SSB, MRPS18B | C3AR1 591/4885FOLH1 191/4885ALOX15 303/4885 |
| US-20260137687-A1 | GTPase INHIBITORS AND USES THEREOF | SIN3A, NOX3, GNAI3 | C3AR1 658/4885FOLH1 4203/4885ALOX15 4338/4885 |
| US-20250255795-A1 | CYCLIC PEROXIDE, OXIDATION REACTION PRODUCT, METHOD FOR PRODUCING OXIDATION REACTION PRODUCT, AND APPLICATIONS OF THESE | CBR1, DUOX1, AOX1 | C3AR1 700/4885FOLH1 4165/4885ALOX15 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.